1,029
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Minimum Contact Time of 1.25%, 2.5%, 5%, and 10% Benzoyl Peroxide for a Bactericidal Effect Against Cutibacterium acnes

, ORCID Icon, , , , & show all
Pages 403-409 | Published online: 10 Mar 2022

References

  • Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(6 Suppl):9–25.
  • Dréno B, Pécastaings S, Corvec S, et al. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32:5–14. doi:10.1111/jdv.15043
  • Cong T-X, Hao D, Wen X, et al. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res. 2019;311(5):337–349. doi:10.1007/s00403-019-01908-x
  • Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10(15):2555–2562. doi:10.1517/14656560903277228
  • Leyden JJ, Preston N, Osborn C, et al. In-vivo effectiveness of Adapalene 0.1%/benzoyl peroxide 2.5% gel on antibiotic-sensitive and resistant Propionibacterium acnes. J Clin Aesthet Dermatol. 2011;4(5):22.
  • Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973. doi:10.1016/j.jaad.2015.12.037
  • Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2):S1–S23. doi:10.1016/j.jaad.2017.09.078
  • Barbieri JS, Spaccarelli N, Margolis DJ, et al. Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J Am Acad Dermatol. 2019;80(2):538–549. doi:10.1016/j.jaad.2018.09.055
  • Feldman SR, Chen DM. How patients experience and manage dryness and irritation from acne treatment. J Drugs Dermatol. 2011;10(6):605–608.
  • Del Rosso JQ, Leyden JJ, Thiboutot D, et al. Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists. Cutis. 2008;82(Suppl 2):5–12.
  • Del Rosso JQ. Benzoyl peroxide cleansers for the treatment of acne vulgaris: status report on available data. Cutis. 2008;82(5):336–342.
  • Okamoto K, Ikeda F, Kanayama S, et al. In vitro antimicrobial activity of benzoyl peroxide against Propionibacterium acnes assessed by a novel susceptibility testing method. J Infect Chemother. 2016;22(6):426–429. doi:10.1016/j.jiac.2015.12.010
  • Laochunsuwan A, Taweechotipatr M, Udompataikul M, Karnjanawanichkul W. In vitro study of antibiotic susceptibility of Propionibacterium acnes strains isolated from acne vulgaris patients. J Med Assoc Thai. 2017;100(10):24–31.
  • Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev. 2013;26(3):526–546. doi:10.1128/CMR.00086-12
  • Hoben HJ, Somasegaran P. Comparison of the pour, spread, and drop plate methods for enumeration of Rhizobium spp. in inoculants made from presterilized peat. Appl Environ Microbiol. 1982;44(5):1246–1247. doi:10.1128/aem.44.5.1246-1247.1982
  • Cove J, Holland K. The effect of benzoyl peroxide on cutaneous micro‐organisms in vitro. J Appl Bacteriol. 1983;54(3):379–382. doi:10.1111/j.1365-2672.1983.tb02631.x
  • Decker LC, Deuel DM, Sedlock DM. Role of lipids in augmenting the antibacterial activity of benzoyl peroxide against Propionibacterium acnes. Antimicrob Agents Chemother. 1989;33(3):326–330. doi:10.1128/AAC.33.3.326
  • Eady E, Farmery M, Ross J, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic‐sensitive and‐resistant skin bacteria from acne patients. Br J Dermatol. 1994;131(3):331–336. doi:10.1111/j.1365-2133.1994.tb08519.x
  • Farmery M, Jones’ C, Eady E, et al. In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. J Dermatolog Treat. 1994;5(2):63–65. doi:10.3109/09546639409084531
  • Nakatsuji T, Kao MC, Fang JY, et al. Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol. 2009;129(10):2480–2488. doi:10.1038/jid.2009.93
  • Pannu J, McCarthy A, Martin A, et al. In vitro antibacterial activity of NB-003 against Propionibacterium acnes. Antimicrob Agents Chemother. 2011;55(9):4211–4217. doi:10.1128/AAC.00561-11
  • Blaskovich MAT, Elliott AG, Kavanagh AM, et al. In vitro antimicrobial activity of acne drugs against skin-associated bacteria. Sci Rep. 2019;9(1):14658. doi:10.1038/s41598-019-50746-4
  • Bojar R, Cunliffe W, Holland K. The short‐term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol. 1995;132(2):204–208. doi:10.1111/j.1365-2133.1995.tb05014.x